Synapse - Even Rustad

Results (13)

Long-term sustained minimal residual disease (MRD) negativity in multiple myeloma patients treated with lenalidomide maintenance therapy: A clinical and correlative phase 2 study

Meeting Abstract

Landgren, O.; Mastey, D.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Salcedo, M.; more...
Blood (2019)

Fulltext@MSK | Save

Plasma cell myeloma residual disease quantitation using a next-generation sequencing-based IGH clonal rearrangement assay with the aid of a "spike-in" clonal sequence

Meeting Abstract

Ho, C.; Syed, M.; Yu, W.; Petrova-Drus, K.; Yao, J. J.; Moung, C.; Chang, J.; Benhamida, J.; Vanderbilt, C.; Roshal, M.; more...
Blood (2019)

Fulltext@MSK | Save

Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow based flow cytometry for tracking measurable residual disease (MRD) in patients with multiple myeloma

Meeting Abstract

Eveillard, M.; Rustad, E. H.; Roshal, M.; Zhang, Y.; Ciardiello, A. K.; Korde, N.; Hultcrantz, M.; Hassoun, H.; Smith, E. L.; Lesokhin, A. M.; more...
Blood (2019)

Fulltext@MSK | Save

Revealing the impact of recurrent and rare structural variations in multiple myeloma

Meeting Abstract

Rustad, E. H.; Yellapantula, V.; Glodzik, D.; Gundem, G.; Leongamornlert, D. A.; Campbell, P. J.; Papaemmanuil, E.; Landgren, O.; Maura, F.
Blood (2019)

Fulltext@MSK | Save

Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy provides unprecedented MRD negativity rates in newly diagnosed multiple myeloma: A clinical and correlative phase 2 study